Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy.
Clin Microbiol Infect. 2011 Sep;17(9):1352-5. doi: 10.1111/j.1469-0691.2011.03563.x. Epub 2011 Jun 2.
We analysed trends of human immunodeficiency virus type 1 (HIV-1) drug resistance during 2007-2009 in the Italian national HIV drug resistance database 'ARCA'. Prevalence of resistance in each year was examined on the basis of the presence of major International AIDS Society-2009 mutations. Predictors of resistance were analysed by multivariable logistic regression. Nine hundred and sixty-six patients were selected. Resistance to nucleoside reverse transcriptase inhibitors and protease inhibitors showed a significant decline with respect to previous surveys. Resistance to any class of drug and three drug classes remained stable. Independent predictors of three-class resistance were the number of treatment regimens experienced, prior suboptimal nucleoside reverse transcriptase inhibitor therapy and the current use of ritonavir-boosted protease inhibitors.
我们分析了 2007-2009 年意大利国家 HIV 耐药性数据库“ARCA”中人类免疫缺陷病毒 1 型(HIV-1)耐药性的趋势。根据主要的国际艾滋病协会 2009 年突变的存在,检查了每年的耐药率。通过多变量逻辑回归分析了耐药的预测因素。选择了 966 名患者。与以前的调查相比,核苷逆转录酶抑制剂和蛋白酶抑制剂的耐药性显著下降。对任何类别的药物和三类药物的耐药性保持稳定。三类药物耐药的独立预测因素是治疗方案的数量、先前核苷逆转录酶抑制剂治疗效果不佳和目前使用利托那韦增效蛋白酶抑制剂。